Entering text into the input field will update the search result below

Circling In On Cidara Therapeutics

May 01, 2020 2:34 PM ETCidara Therapeutics, Inc. (CDTX)29 Comments


  • Today, we take an in-depth look at Cidara Therapeutics.
  • This San Diego based 'Tier 4' biopharma concern is developing anti-fungal candidates.
  • A full analysis is provided in the paragraphs below.
  • I do much more than just articles at The Biotech Forum: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »

I accept chaos, I'm not sure whether it accepts me."― Bob Dylan

Today, we take an in-depth look at small 'Tier 4' biopharma concern on the west coast focused on the anti-fungal space. It has come up in conversation a few times on my instablogs over the past few months. A full analysis is provided in the paragraphs below.

Company Overview

Cidara Therapeutics (NASDAQ:CDTX) is a San Diego, California-based clinical-stage biotechnology company that IPO'd in 2015. The company aims to develop drugs for severe fungal or viral infections. The company's lead product candidate is Rezafungin, which is an echinocandin antifungal. The idea is that the drug will gain market share by possessing improved pharmacokinetics relative to existing echinocandins, which possesses the potential for expanded utility across various patient settings.

Additionally, the company seeks to create long-term shareholder value through leveraging their Cloudbreak platform, which is their novel approach to take on life-threatening infectious disease. The Cloudbreak technology is the first immunotherapy discovery platform explicitly designed to create compounds that kill pathogens directly and can direct and mobilize one's immune cells to attack and destroy bacterial, fungal, or viral pathogens. Recently, the company announced that they have selected CD377 to pursue clinical development. The company hopes that the drug will become the first antiviral drug conjugate that acts as a universal, once-per-season, prevention and treatment of influenza. Cidara Therapeutics has a market capitalization of roughly $115 million and trades for around $2.75 a share.


Source: Company Presentation


Rezafungin is a novel molecule in the echinocandin class of antifungals, which is the safest class of antifungals. It's a broad-spectrum, long-lasting echinocandin. In vivo research has shown robust activity when pitted against a variety of strains: Candida spp, Aspergillus spp, Pneumocystis spp, Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum. The drug is addressing the unmet needs of being first-line therapy for candidemia and

Live Chat on The Biotech Forum continues to be very active with new trade and the lucrative covered call ideas available thanks to the spike in market volatility throughout the trading day. If you join the The Biotech Forum today by clicking HERE you will automatically get access to our model portfolio, Live Chat, investment archives and our next 'option play of the week' coming out Monday targeting a potential 40% return over the next six months.

This article was written by

Bret Jensen profile picture
Finding tomorrow's big winners in the lucrative biotech sector

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I am/we are long PRTK. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.